Nanobodies TM targeting amyloid beta as potential therapeutics for Alzheimer's disease

Author	Search for: Merchiers, Pascal; Search for: van Dooren, Tom; Search for: Van der Auwera, Ingrid; Search for: Abulrob, Abedelnasser¹; Search for: Lauwereys, Marc; Search for: Roland, Bart; Search for: Borghraef, Peter; Search for: Decruy, Tine; Search for: Lox, Marleen; Search for: Hoogenboom, Hennie R.; Search for: Wera, Stefaan; Search for: Stanimirovic, Danica¹; Search for: de Haard, Hans; Search for: van Leuven, Fred
Affiliation	National Research Council of Canada. NRC Institute for Biological Sciences
Format	Text, Article
Subject	amyloid beta; Alzheimer's disease; aanobodies; passive immunotherapy
Abstract	Active and passive immunization strategies targeting amyloid beta are currently being developed as a potential therapy to treat Alzheimer's disease (AD). Both approaches have shown efficacy in animal models, while passive vaccination is expected to be safer in the clinical context. We have explored the use of amyloid beta targeting Nanobodies for passive immunotherapy of AD. Nanobodies are 12-15 kDa protein domains derived from camelid Heavy-Chain antibodies with unique characteristics that offer many advantages over the use of conventional monoclonal antibodies.
Language	English
Peer reviewed	Yes
NPARC number	21275177
Export citation	Export as RIS
Report a correction	Report a correction (opens in a new tab)
Record identifier	80d443d9-e752-4846-96d9-b7d20f33225c
Record created	2015-05-22
Record modified	2020-04-22